Nexterone and Sovaldi

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using amiodarone together with sofosbuvir can cause excessive slowing of your heart rate that can lead to serious or life-threatening cardiac complications. This is most likely to occur early on after you start treatment with these medications, especially within the first 48 hours. It may be alright for you to receive both medications; however, treatment should be initiated under close medical supervision. Your first dose of medication must be taken at your doctor's office or in a hospital where they can monitor your heart rate, and you will need to have your heart rate monitored every day for at least the first 2 weeks of treatment. Contact your doctor if you develop dizziness, lightheadedness, fainting, shortness of breath, confusion, weakness, excessive tiredness, chest pain, or heart palpitations at any time during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Severe, life-threatening, symptomatic bradycardia has been reported during coadministration of amiodarone with ledipasvir-sofosbuvir or with sofosbuvir taken in combination with another direct acting antiviral for the treatment of hepatitis C, such as daclatasvir or simeprevir. The mechanism of interaction has not been delineated. Postmarketing adverse event reports include one death due to cardiac arrest, three patients requiring placement of a pacemaker to regulate cardiac rhythm, and other patients who recovered following discontinuation of either the hepatitis C drugs or amiodarone, or both. Bradycardia has generally occurred within hours to days, but in some cases up to 2 weeks after initiating hepatitis C antiviral treatment. Additional risk factors may include concomitant use of beta blockers, underlying cardiac comorbidities, and advanced liver disease.

MANAGEMENT: Concomitant use of amiodarone with sofosbuvir-containing hepatitis C antiviral treatment is not recommended. However, if coadministration is unavoidable, some authorities recommend cardiac monitoring in an inpatient hospital setting for the first 48 hours, followed by subsequent cardiac monitoring every day for at least the first 2 weeks of treatment. Similar cardiac monitoring is recommended for patients in whom amiodarone was discontinued just prior to starting hepatitis C antiviral treatment due to the long half-life of amiodarone. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate symptomatic bradycardia such as dizziness, lightheadedness, confusion, memory problems, fainting, malaise, weakness, excessive tiredness, palpitation, chest pain, irregular heart rhythm, shortness of breath, or syncope.

Nexterone

Generic Name: amiodarone

Brand name: Nexterone, Pacerone, Cordarone

Synonyms: n.a.

What is Nexterone?

Sovaldi

Generic Name: sofosbuvir

Brand name: Sovaldi

Synonyms: n.a.

What is Sovaldi?